Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2017 · 10-Q
Revenue$6.56M$6.56M+176.3% vs Q2 2016 Net Income-$14.47M-$14.47MN/M vs Q2 2016 EPS Diluted-$0.47-$0.47N/M vs Q2 2016 Operating Income-$15,056,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,229,000N/M Margins · derivedOperating margin-229.4%+400.1 pt vs Q2 2016
Net margin-220.6%+387.3 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 8, 2017 · 39 d after period end